Drug Profile

Research programme: CNS disorders therapeutics - CAMP4 Therapeutics

Latest Information Update: 21 Jul 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator CAMP4 Therapeutics
Class Antisense oligonucleotides; Neuroprotectants
Mechanism of Action NAV1.1 voltage-gated sodium channel expression stimulants; Progranulin protein stimulants; RNA interference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

20 Jul 2022 CAMP4 Therapeutics announces intention to submit IND application for Dravet syndrome in mid-2023
20 Jul 2022 CAMP4 Therapeutics plans a clinical trial for Dravet syndrome in mid-2023
25 Jun 2021 CNS disorders antisense oligonucleotide therapeutics are available for licensing as of 25 Jun 2021. https://www.camp4tx.com/about-camp4/investors/

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com